É. Alamartine

Excessive body weight as a new independent risk factor for clinical and pathological progression in primary IgA nephritis

Fabrice Bonnet, Carole Deprele, Agnès Sassolas et al. · American Journal of Kidney Diseases · 2001 · 310 citations

Obesity, Glomerulonephritis, Urology +8

Prognostic Factors in Mesangial IgA Glomerulonephritis: An Extensive Study With Univariate and Multivariate Analyses

É. Alamartine, Jean-Charles Sabatier, Claude Guérin et al. · American Journal of Kidney Diseases · 1991 · 278 citations

Glomerular Disease, Prognostic Factors, Pathology +16

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

Brad H. Rovin, Jonathan Barratt, Hiddo J.L. Heerspink et al. · The Lancet · 2023 · 224 citations · Full text

Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy

Jonathan Barratt, Richard Lafayette, Jens Kristensen et al. · Kidney International · 2022 · 205 citations · Full text

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

Hiddo J.L. Heerspink, Jai Radhakrishnan, Charles E. Alpers et al. · The Lancet · 2023 · 203 citations · Full text

Glomerulonephritis, Active-controlled Clinical Trial, Renal Function +9